NCT00794859View on ClinicalTrials.gov

Sorafenib in Previously Treated Malignant Mesothelioma

PHASE2UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2009

Conditions
Mesothelioma
Interventions
DRUG

Sorafenib

400mg twice daily

Trial Locations (1)

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

King's College London

OTHER